Evidence map›Paper›PMID 28971615›Full record

Trial reportPharmacology research & perspectives2017

Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study.

Jutta Beier, Rainard Fuhr, Beatriz Seoane, Eric Massana, Gonzalo de Miquel, Helena Pujol, Sandrine Ruiz

Open access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacology research & perspectives, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handbook of experimental pharmacology · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Jutta Beierinsaf Respiratory Research Institute, Biebricher Allee 34, 65187, Wiesbaden, Germany.
Rainard FuhrPAREXEL International GmbH, Klinikum Westend, Haus 17, D-14050, Berlin, Germany.
Beatriz SeoaneAstraZeneca, Avda. Diagonal 615, 08028, Barcelona, Spain.
Eric MassanaAlmirall Research and Development Centre, Laureà Miró, 408-410, 08980, Sant Feliu de Llobregat, Barcelona, Spain.
Gonzalo de MiquelFormer employee of AstraZeneca, Avda. Diagonal 615, 08028, Barcelona, Spain.
Helena PujolAstraZeneca, Avda. Diagonal 615, 08028, Barcelona, Spain.
Sandrine RuizAstraZeneca, Avda. Diagonal 615, 08028, Barcelona, Spain.
AstraZeneca (Spain) · ESAlmirall (Spain) · ESPAREXEL International (United Kingdom) · GBRespiratory Research Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abediterol is a once-daily, long-acting β

Indexed as

Adrenergic beta-2 Receptor AgonistsAdultAsthmaCross-Over StudiesDose-Response Relationship, DrugDrug Administration ScheduleForced Expiratory VolumeHumansMaleMiddle AgedQuinolonesSpirometryTreatment Outcome5-(2-((6-(2,2-difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-oneAdrenergic beta-2 Receptor AgonistsQuinolonesAsthmabronchodilationchronic respiratory diseaseLABA

Identifiers

PMID28971615
PMCPMC5625160
OpenAlexW2759583910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.